Partner Content Partner Content 4 Reasons Why You Shouldn't Ignore CDISC Data Standards CDISC standards
Partner Content Partner Content What the Best Clinical Study Build Pros Do (and You Should T... Master Clinical Study Build with ryze!
Partner Content Partner Content The ryze-elluminate integration to maximise automation in cl... The ryze-elluminate integration
Partner Content Partner Content Formedix launches Community Forum to support the clinical tr... Formedix launches the ryze Community Forum
Partner Content Partner Content Formedix Partnered with CDISC to Give Free Access to CDASH-C... Free access to CDASH-Compliant eCRFs
Partner Content Partner Content How the Formedix ryze Visual Define-XML Editor Gives You Fas... Creating Define-XML files has never been easier!
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
